Cost-Effectiveness of Azacitidine Compared with Low-Doses of Chemotherapy (LDC) in Myelodysplastic Syndrome (MDS):

Global & Regional Health Technology Assessment

MyrnaCandelaria Hernández¹ 

关键词: Acute myeloid leukemia;    Cost-effectiveness;    Effectiveness;    Intermediate-2;    high-risk;    Myelodysplastic syndrome;   

DOI  :  10.5301/grhta.5000261

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

ABSTRACTIntroductionMyelodysplastic syndrome (MDS) comprises a group of clonal hematological disorders, characterized by ineffective hematopoiesis and progressive bone marrow failure. It increases the risk of transformation to acute myeloid leukemia (AML). Therapeutic benefit should include overall survival increase (OS), hematological improvement, transfusion dependence and time to progression to AML decrease.ObjectiveAssess, from a Mexican health-care perspective, the cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) plus best supportive care (BSC) for the treatment of adult patients with intermediate-2 and high-risk MDS, who are not eligible for hematopoietic stem-cell transplantation. We developed a cost-effectiveness survival analysis model of three stages: MDS, AML, and death. OS and costs are extrapolated beyond three-year time horizon. Discount rate of 5% was applied. To estimate the model cycle probability transition to mortality state, survival curves were construct...

【 授权许可】

CC BY